Point72 Asset Management
SLN

Point72 Asset Management’s Silence Therapeutics SLN Stock Holding History

Point72 Asset Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$631K Buy
119,711
+5,641
+5% +$31.1K ﹤0.01% 3021
2025
Q4 		$694K Buy
+114,070
New +$730K ﹤0.01% 3066
2025
Q2 		– Sell
-16,032
Closed -$45.2K – 2578
2025
Q1 		$45.2K Sell
16,032
-617,068
-97% -$3.01M ﹤0.01% 1957
2024
Q4 		$4.36M Buy
633,100
+165,300
+35% +$2.13M 0.01% 997
2024
Q3 		$8.5M Buy
467,800
+321,300
+219% +$5.98M 0.02% 701
2024
Q2 		$2.78M Buy
146,500
+138,300
+1,687% +$2.94M 0.01% 1002
2024
Q1 		$177K Buy
+8,200
New +$178K ﹤0.01% 1921
2023
Q3 		– Sell
-86,700
Closed -$477K – 2838
2023
Q2 		$477K Sell
86,700
-262,762
-75% -$1.58M ﹤0.01% 1275
2023
Q1 		$2.17M Sell
349,462
-21,100
-6% -$249K 0.01% 963
2022
Q4 		$5.65M Sell
370,562
-180,313
-33% -$2.36M 0.02% 719
2022
Q3 		$5.53M Buy
550,875
+300,875
+120% +$3.17M 0.02% 689
2022
Q2 		$2.96M Hold
250,000
– – 0.01% 844
2022
Q1 		$4.75M Hold
250,000
– – 0.02% 719
2021
Q4 		$5.97M Buy
+250,000
New +$5.79M 0.02% 632

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Point72 Asset Management's SLN Position: Q1 2026 in Review

Point72 Asset Management increased its Silence Therapeutics (SLN) stake by 4.9% in Q1 2026, buying an estimated $31.1K and bringing the position to 119,711 shares worth $631K. The position accounts for ﹤0.01% of the portfolio, ranked #3021.

Point72 Asset Management first reported a position in SLN in Q4 2021 and has held it in 14 quarters since. The position peaked at $8.5M in Q3 2024. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • Point72 Asset Management held 119,711 shares of Silence Therapeutics worth $631K as of Q1 2026.
  • Point72 Asset Management bought 5,641 Silence Therapeutics shares in Q1 2026, an estimated $31.1K.
  • Silence Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #3021 holding.
  • Point72 Asset Management first reported a position in Silence Therapeutics in Q4 2021 and has held it in 14 quarters since.
  • Point72 Asset Management's Silence Therapeutics position peaked at $8.5M in Q3 2024.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.